A letter (PDF) issued by SAMHSA and the FDA emphasizes that counseling and other services should not be prerequisites for a patient to receive medications for opioid use disorder. Practitioners must work collaboratively with patients, meeting them where they are, to create supportive and tailored treatment plans.
